|
1
|
Nagorney DM and McPherson GA: Carcinoma of
the gallbladder and extrahepatic bile ducts. Semin Oncol.
15:106–115. 1988.PubMed/NCBI
|
|
2
|
Zhu AX, Hong TS, Hezel AF and Kooby DA:
Current manage- ment of gallbladder carcinoma. Oncologist.
15:168–181. 2010. View Article : Google Scholar
|
|
3
|
Takahashi T, Shivapurkar N, Riquelme E, et
al: Aberrant promoter hypermethylation of multiple genes in
gallbladder carcinoma and chronic cholecystitis. Clin Cancer Res.
10:6126–6133. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Unoki M, Nishidate T and Nakamura Y:
ICBP90, an E2F-1 target, recruits HDAC1 and binds to methyl-CpG
through its SRA domain. Oncogene. 23:7601–7610. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Jeanblanc M, Mousli M, Hopfner R, et al:
The retinoblastoma gene and its product are targeted by ICBP90: a
key mechanism in the G1/S transition during the cell cycle.
Oncogene. 24:7337–7345. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Geng Y, Gao Y, Ju H and Yan F: Diagnostic
and prognostic value of plasma and tissue ubiquitin-like,
containing PHD and RING finger domains 1 in breast cancer patients.
Cancer Sci. 104:194–199. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Wang F, Zhang P, Ma Y, et al: NIRF is
frequently upregulated in colorectal cancer and its oncogenicity
can be suppressed by let-7a microRNA. Cancer Lett. 314:223–231.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Unoki M, Kelly JD, Neal DE, Ponder BA,
Nakamura Y and Hamamoto R: UHRF1 is a novel molecular marker for
diagnosis and the prognosis of bladder cancer. Br J Cancer.
101:98–105. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Unoki M, Daigo Y, Koinuma J, Tsuchiya E,
Hamamoto R and Nakamura Y: UHRF1 is a novel diagnostic marker of
lung cancer. Br J Cancer. 103:217–222. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Babbio F, Pistore C, Curti L, et al: The
SRA protein UHRF1 promotes epigenetic crosstalks and is involved in
prostate cancer progression. Oncogene. 31:4878–4887. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Yang C, Wang Y, Zhang F, et al: Inhibiting
UHRF1 expression enhances radiosensitivity in human esophageal
squamous cell carcinoma. Mol Biol Rep. 40:5225–5235. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Pi JT, Lin Y, Quan Q, Chen LL, Jiang LZ,
Chi W and Chen HY: Overexpression of UHRF1 is significantly
associated with poor prognosis in laryngeal squamous cell
carcinoma. Med Oncol. 30:6132013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Tien AL, Senbanerjee S, Kulkarni A, et al:
UHRF1 depletion causes a G2/M arrest, activation of DNA
damage response and apoptosis. Biochem J. 435:175–185.
2011.PubMed/NCBI
|
|
14
|
Arima Y, Hirota T, Bronner C, et al:
Down-regulation of nuclear protein ICBP90 by
p53/p21Cip1/WAF1-dependent DNA damage checkpoint signals
contributes to cell cycle arrest at G1/S transition. Genes Cells.
9:131–142. 2004.PubMed/NCBI
|
|
15
|
Lazcano-Ponce EC, Miquel JF, Muñoz N, et
al: Epidemiology and molecular pathology of gallbladder cancer. CA
Cancer J Clin. 51:349–364. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Jenkins Y, Markovtsov V, Lang W, et al:
Critical role of the ubiquitin ligase activity of UHRF1, a nuclear
RING finger protein, in tumor cell growth. Mol Biol Cell.
16:5621–5629. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Porter AG and Jänicke RU: Emerging roles
of caspase-3 in apoptosis. Cell Death Differ. 6:99–104. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Vermeulen K, Van Bockstaele DR and
Berneman ZN: Apoptosis: mechanisms and relevance in cancer. Ann
Hematol. 84:627–639. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Guan D, Factor D, Liu Y, Wang Z and Kao
HY: The epigenetic regulator UHRF1 promotes ubiquitination-mediated
degradation of the tumor-suppressor protein promyelocytic leukemia
protein. Oncogene. 32:3819–3828. 2013. View Article : Google Scholar
|
|
20
|
Chang HJ, Yoo BC, Kim SW, Lee BL and Kim
WH: Significance of PML and p53 protein as molecular prognostic
markers of gallbladder carcinomas. Pathol Oncol Res. 13:326–335.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Krieghoff-Henning E and Hofmann TG: Role
of nuclear bodies in apoptosis signalling. Biochim Biophys Acta.
1783:2185–2194. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Reineke EL, Liu Y and Kao HY:
Promyelocytic leukemia protein controls cell migration in response
to hydrogen peroxide and insulin-like growth factor-1. J Biol Chem.
285:9485–9492. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Kim WH, Kang KH, Kim MY and Choi KH:
Induction of p53-independent p21 during ceramide-induced G1 arrest
in human hepatocarcinoma cells. Biochem Cell Biol. 78:127–135.
2000. View
Article : Google Scholar : PubMed/NCBI
|
|
24
|
Zuo S, Liu C, Wang J, et al: IGFBP-rP1
induces p21 expression through a p53-independent pathway, leading
to cellular senescence of MCF-7 breast cancer cells. J Cancer Res
Clin Oncol. 138:1045–1055. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Shen Y: Advances in the development of
siRNA-based therapeutics for cancer. IDrugs. 11:572–578.
2008.PubMed/NCBI
|
|
26
|
Unoki M, Kumamoto K and Harris CC: ING
proteins as potential anticancer drug targets. Curr Drug Targets.
10:442–454. 2009. View Article : Google Scholar : PubMed/NCBI
|
